Brit J Cancer:在外周血和前列腺癌风险中,染色体8q24 DNA甲基化的预期研究

2017-05-09 AlexYang MedSci原创

染色体8q24表现为几种癌症的重要遗传敏感区域,包括了前列腺癌。然而,该区域的DNA的甲基化对癌症贡献的风险却所知甚少。最近,研究人员预期性的评估了8q24区域DNA甲基化与前列腺癌的关系,实验材料为利用从694名前列腺癌案例(包括172名恶性案例)的诊断前血样和703名在前列腺、肺、大肠和卵巢癌筛选临床实验中的对照,并利用逻辑回归评估让步比和95%置信区间。研究结果发现,在多项检验调整后,50个

染色体8q24表现为几种癌症的重要遗传敏感区域,包括了前列腺癌。然而,该区域的DNA的甲基化对癌症贡献的风险却所知甚少。最近,研究人员预期性的评估了8q24区域DNA甲基化与前列腺癌的关系,实验材料为利用从694名前列腺癌案例(包括172名恶性案例)的诊断前血样和703名在前列腺、肺、大肠和卵巢癌筛选临床实验中的对照,并利用逻辑回归评估让步比和95%置信区间。

研究结果发现,在多项检验调整后,50个满足质量控制的CpG位点,没有位点表现出显著性的差异(q>0.05),研究人员鉴定了8个与前列腺癌相关的位点(Ptrend<0.05),包括了6个在POU5F1B中相关的(Spearman ρ: 0.20-0.5)位点和2个基因间的位点(最显著的位点:Chr8:128428897 in POU5F1B, Ptrend=0.01)。研究同时也鉴定了两个在MYC中相关的(ρ=0.39)位点(Chr8:128753187 and Chr8:128753154),这两个位点与恶性疾病相关(Ptrend=0.02 and 0.03),而与非恶性疾病无关(Ptrend=0.70 and 0.20; Pheterogeneity=0.01 and 4.6 × 10-3)。该项研究中,这些发现支持了调整后的8q24前列腺癌变异位点。最后,研究人员指出,尽管需要重复,他们的研究仍旧提供了8q24DNA甲基化水平与前列腺癌风险相关的一些证据。

原始出处:

Kathryn Hughes Barry, Lee E Moore, Joshua N Sampson et al. Prospective study of DNA methylation at chromosome 8q24 in peripheral blood and prostate cancer risk. Brit J Cancer. 02 May 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061616, encodeId=b51e206161612, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Feb 10 09:52:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022556, encodeId=2cc920225562e, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Sat Aug 12 10:52:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331640, encodeId=720413316402e, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Thu May 11 10:52:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578523, encodeId=139d15e852390, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Thu May 11 10:52:00 CST 2017, time=2017-05-11, status=1, ipAttribution=)]
    2018-02-10 sjq027
  2. [GetPortalCommentsPageByObjectIdResponse(id=2061616, encodeId=b51e206161612, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Feb 10 09:52:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022556, encodeId=2cc920225562e, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Sat Aug 12 10:52:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331640, encodeId=720413316402e, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Thu May 11 10:52:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578523, encodeId=139d15e852390, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Thu May 11 10:52:00 CST 2017, time=2017-05-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2061616, encodeId=b51e206161612, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Feb 10 09:52:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022556, encodeId=2cc920225562e, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Sat Aug 12 10:52:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331640, encodeId=720413316402e, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Thu May 11 10:52:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578523, encodeId=139d15e852390, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Thu May 11 10:52:00 CST 2017, time=2017-05-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2061616, encodeId=b51e206161612, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Feb 10 09:52:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022556, encodeId=2cc920225562e, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Sat Aug 12 10:52:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331640, encodeId=720413316402e, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Thu May 11 10:52:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578523, encodeId=139d15e852390, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Thu May 11 10:52:00 CST 2017, time=2017-05-11, status=1, ipAttribution=)]

相关资讯

PLoS Genet:SPOP突变前列腺癌中,INF2调控的线粒体分裂异常调节

前列腺癌外显子组和基因组的下一代测序鉴定了大量的遗传变异位点。SPOP(斑点型POZ蛋白)是初级前列腺癌中最经常发生突变的基因之一,表明了SPOP是一个前列腺癌发生和发展的潜在驱使因子。然而,SPOP图片怎样导致前列腺癌的发病机理仍旧所知甚少。SPOP可以作为CUL3-RBX1 E3泛素连接酶复合物的接头蛋白并且可以招募泛素化底物以便随后的降解。内质网定位的甲酸精蛋白倒甲酸精2(INF2)可以调控

Oncogenesis:二甲双胍可以抑制SUV39H1调控的前列腺癌细胞迁移

前列腺癌(PCa)是男性癌症相关死亡的主要原因,很大程度上是由于不能治愈的远距离转移。二甲双胍是一种广泛应用于抗糖尿病2型的药物,研究发现,该药能够减少癌症风险并且能取得更好的诊断最近,有研究人员发现,二甲双胍能抑制PCa细胞的迁移,而PCa细胞的迁移与肿瘤转移能力相关。发病机理和肿瘤进展与肿瘤细胞中基因的异常表达相关,主要是通过表观修饰,比如DNA甲基化和组蛋白修饰。研究人员发现,SUV39H

JCO:雄激素受体剪接变体与前列腺癌对恩扎鲁胺和阿比特龙耐药间的关系

雄激素受体在前列腺癌的发展中起着非常重要的作用,通过雄激素剥夺治疗来抑制雄激素受体成为转移性前列腺癌的起始治疗。大部分病人,对雄激素剥夺治疗会有反应,但是随后这部分病人会表现出不同形式的复发及出现去势抵抗性前列腺癌。现在已经清楚是雄激素受体通过增加表达及扩增在去势抵抗性前列腺癌中仍起驱动作用。使得雄激素受体在去势抵抗中起作用的另一机理,即通过肾上腺中的前体类固醇使得瘤内合成雄激素(睾酮或二氢睾酮)

Prostate Cancer P D:机器人辅助的根治性前列腺癌切除术治疗临床高风险前列腺癌病人的功能恢复

最近,研究人员评估了机器人辅助的根治性前列腺癌切除术(RARP)治疗临床高风险前列腺癌病人(PCa)的3年排尿控制(UC)和性功能(SF)恢复状况。2001年和2004年,研究人员对美国和欧洲的两个三级医疗中心维护的数据库,即769名患有D'Amico高风险PCa并且经历RARP的病人资料,进行了回顾性分析。研究人员分别利用术前和术后Cox比例风险回归模型对从RARP与UC和SF的恢复的时间关系进

Prostate Cancer P D:前列腺切除术后的补救放射疗法后,受益于雄激素阻断治疗的选择的男性

对于哪一名男性能够在前列腺切除术后补救放射疗法(SRT)中加入雄激素阻断治疗(ADT)受益最大,人们对这个问题仍旧不清楚。最近,有研究人员评估了ADT对SRT在前列腺切除术后具有增加的或者永久PSA男性的成功生存率(FFS)的影响。研究人员鉴定了在1987年到2010年,前列腺切除术后接受SRT的男性患者,并根据单个的SRT后失败的风险,利用独立递归分级指数(RPA)鉴定了有利的、中间的和不利的小

CLIN CANCER RES:前列腺切除术前新辅助Enzalutamide治疗

前列腺癌需要雄激素受体活化。理想的雄激素受体拮抗作用可以有效缩小局部病灶并抑制或清除微转移灶。CLIN CANCER RES近期发表了一篇文章,研究前列腺切除术前雄激素受体拮抗剂enzalutamide(enza)单独或与dutasteride(dut)及leuprolide联合新辅助治疗(enza/dut/LHRHa)的疗效。